{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:24:43Z","timestamp":1770967483549,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To identify prognostic factors and develop nomograms predicting short-term mortality and relapse in pediatric\n                      <jats:italic>RUNX1::RUNX1T1<\/jats:italic>\n                      -positive AML, thereby enabling individualized risk assessment and optimizing clinical management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 136 pediatric patients with\n                      <jats:italic>RUNX1::RUNX1T1<\/jats:italic>\n                      -positive AML who achieved morphologic complete remission (CR) after one induction course under AML-CAMS-2009 or AML-CAMS-2016 regimen. Least absolute shrinkage and selection operator (LASSO) and multivariable Cox regression identified independent predictors of 3-year overall survival (OS) and relapse-free survival (RFS). Nomograms were built from these predictors. Model performance was assessed by time-dependent receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA), and concordance index (C-index), with internal validation performed by bootstrap resampling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High-Risk measurable residual disease (MRD), treatment regimen, and diagnostic white blood cell (WBC) group (\u226520\u00d710\u2079\/L vs. &amp;lt;20\u00d710\u2079\/L) independently predicted OS. For RFS, independent predictors were percentage of bone marrow blasts by flow cytometry (BM blasts [FCM]), extramedullary infiltration (EMI), High-Risk MRD, treatment regimen, and WBC group. Nomograms demonstrated strong discrimination and calibration with superior clinical net benefit versus any single predictor. Nomogram-derived scores stratified patients into prognostically distinct subgroups with significant differences in OS and RFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study established internally validated 3-year OS and RFS nomograms for pediatric\n                      <jats:italic>RUNX1::RUNX1T1<\/jats:italic>\n                      -positive AML with excellent discrimination and clinical utility. Prospective multicenter validation is warranted to confirm the robustness and facilitate clinical adoption.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1744352","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:40:09Z","timestamp":1770964809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram-based prediction models for clinical outcomes in pediatric RUNX1::RUNX1T1-positive acute myeloid leukemia: a retrospective analysis from AML-CAMS serial trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoli","family":"Chen","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihui","family":"Yi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchi","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Ruan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"\u2018Acute myeloid leukemia: a comprehensive review and 2016 update\u2019","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.30","article-title":"Modelling t(8;21) acute myeloid leukaemia - What have we learned","volume":"1","author":"Chin","year":"2020","journal-title":"MedComm"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-3233-2_11","article-title":"RUNX1-ETO leukemia","volume":"962","author":"Lin","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-017-0003-y","article-title":"Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML","volume":"32","author":"Zampini","year":"2018","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-024-00480-z","article-title":"A novel AML1-ETO\/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2019.01.010","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia","volume":"40","author":"Wu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2589","article-title":"Early detection of molecular residual disease and risk stratification for children with acute myeloid leukemia via circulating tumor DNA","volume":"30","author":"Liu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.127","article-title":"Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials","volume":"24","author":"Sander","year":"2010","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12885-023-10965-5","article-title":"Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)","volume":"23","author":"Qiu","year":"2023","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2025.2548966","article-title":"Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials","volume":"66","author":"Zhang","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2025.2547984","article-title":"Mortality and relapse dynamics in AML after three years of complete remission","volume":"66","author":"Urrutia","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-023-00954-z","article-title":"Time independent factors that predict relapse in adults with acute myeloid leukemia","volume":"14","author":"Lim","year":"2024","journal-title":"Blood Cancer J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03665-0","article-title":"Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50\u2009\u00d7\u200910(9)\/L","volume":"118","author":"Zhang","year":"2023","journal-title":"Int J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1947","article-title":"Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"33","author":"Klein","year":"2015","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.exphem.2021.01.007","article-title":"Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1","volume":"96","author":"Wei","year":"2021","journal-title":"Exp Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24834","article-title":"History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission","volume":"92","author":"Rashidi","year":"2017","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029010","article-title":"MRD intervention in AML: A new therapeutic horizon","volume":"147","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70038","article-title":"Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights","volume":"207","author":"Nachmias","year":"2025","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0086-0","article-title":"Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients","volume":"32","author":"H\u00f6llein","year":"2018","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0158-1","article-title":"Response kinetics and factors predicting survival in core-binding factor leukemia","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287293","article-title":"Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia","volume":"110","author":"Yang","year":"2025","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1179\/102453312X13221316477651","article-title":"Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia","volume":"17","author":"Djunic","year":"2012","journal-title":"Hematology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600572673","article-title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","volume":"47","author":"Greenwood","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2512029","article-title":"Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML)","volume":"66","author":"Jany","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000168","article-title":"An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","volume":"4","author":"Al-Harbi","year":"2020","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.3390\/cancers16223855","article-title":"Acute myeloid leukemia: diagnosis and evaluation by flow cytometry","volume":"16","author":"Ally","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.466","article-title":"Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461","volume":"15","author":"Byrd","year":"1997","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.06.009","article-title":"Prognostic impact of extramedullary infiltration in pediatric low-risk acute myeloid leukemia: A retrospective single-center study over 10 years","volume":"20","author":"Hu","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000448209","article-title":"Comparison of clinical efficacy of cytarabine with different regimens in postremission consolidation therapy for adult t(8;21) AML patients: A multicenter retrospective study in China","volume":"136","author":"Gong","year":"2016","journal-title":"Acta Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/08880018.2020.1803462","article-title":"Characteristics and prognosis of pediatric myeloid sarcoma in the cytogenetic context of t(8;21)","volume":"38","author":"Hu","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst","year":"2011","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/\u2013CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leuc\u00e9mies Aigu\u00ebs et Maladies du Sang (GOELAMS) study","volume":"96","author":"Fran\u00e7ois","year":"2011","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1744352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:40:12Z","timestamp":1770964812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1744352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1744352"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1744352","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1744352"}}